BRPI1012344A2 - uso de g-csf para a extensão da janela de tempo terapêutica para terapia de derrame trombolítico. - Google Patents

uso de g-csf para a extensão da janela de tempo terapêutica para terapia de derrame trombolítico.

Info

Publication number: BRPI1012344A2
Authority: BR; Brazil
Prior art keywords: csf; extension; time window; therapeutic time; stroke therapy
Prior art date: 2009-02-17

Application number

BRPI1012344A

Other languages

English (en)

Inventor

Armin Schneider

Marc Fisher

Original Assignee

Sygnis Bioscience Gmbh & Co Kg

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-02-17

Filing date

2010-02-17

Publication date

2016-03-22

2010-02-17 Application filed by Sygnis Bioscience Gmbh & Co Kg filed Critical Sygnis Bioscience Gmbh & Co Kg

2016-03-22 Publication of BRPI1012344A2 publication Critical patent/BRPI1012344A2/pt

Links

208000006011 Stroke Diseases 0.000 title 1
239000003146 anticoagulant agent Substances 0.000 title 1
230000001225 therapeutic effect Effects 0.000 title 1
238000002560 therapeutic procedure Methods 0.000 title 1
230000002537 thrombolytic effect Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Zoology (AREA)
Cardiology (AREA)
Epidemiology (AREA)
Heart & Thoracic Surgery (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

BRPI1012344A 2009-02-17 2010-02-17 uso de g-csf para a extensão da janela de tempo terapêutica para terapia de derrame trombolítico. BRPI1012344A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US15307909P	2009-02-17	2009-02-17
PCT/US2010/024426 WO2010096446A1 (en)	2009-02-17	2010-02-17	Use of g-csf for the extension of the therapeutic time-window of thrombolytic stroke therapy

Publications (1)

Publication Number	Publication Date
BRPI1012344A2 true BRPI1012344A2 (pt)	2016-03-22

Family

ID=42634192

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI1012344A BRPI1012344A2 (pt)	2009-02-17	2010-02-17	uso de g-csf para a extensão da janela de tempo terapêutica para terapia de derrame trombolítico.

Country Status (9)

Country	Link
US (1)	US20120070403A1 (pt)
EP (1)	EP2398493A1 (pt)
JP (1)	JP2012518014A (pt)
CN (1)	CN102316891A (pt)
AU (1)	AU2010216083A1 (pt)
BR (1)	BRPI1012344A2 (pt)
CA (1)	CA2751032A1 (pt)
RU (1)	RU2011138165A (pt)
WO (1)	WO2010096446A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8633158B1 (en)	2012-10-02	2014-01-21	Tarix Pharmaceuticals Ltd.	Angiotensin in treating brain conditions
US9333233B2 (en) *	2014-02-25	2016-05-10	Tarix Pharmaceuticals Ltd.	Methods and compositions for the delayed treatment of stroke
US10478069B2 (en) *	2015-03-12	2019-11-19	The Asan Foundation	Method for estimating time of occurrence of infarct on basis of brain image
AU2018348138A1 (en) *	2017-10-11	2020-04-23	Ambrx, Inc.	Porcine G-CSF variants and their uses
CN110288587A (zh) *	2019-06-28	2019-09-27	重庆同仁至诚智慧医疗科技股份有限公司	一种缺血性脑卒中磁共振影像的病灶识别方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7785601B2 (en) *	2002-12-31	2010-08-31	Sygnis Bioscience Gmbh & Co. Kg	Methods of treating neurological conditions with hematopoietic growth factors

2010
- 2010-02-17 BR BRPI1012344A patent/BRPI1012344A2/pt not_active IP Right Cessation
- 2010-02-17 US US13/201,866 patent/US20120070403A1/en not_active Abandoned
- 2010-02-17 AU AU2010216083A patent/AU2010216083A1/en not_active Abandoned
- 2010-02-17 WO PCT/US2010/024426 patent/WO2010096446A1/en not_active Ceased
- 2010-02-17 RU RU2011138165/15A patent/RU2011138165A/ru not_active Application Discontinuation
- 2010-02-17 CN CN2010800079244A patent/CN102316891A/zh active Pending
- 2010-02-17 EP EP10744229A patent/EP2398493A1/en not_active Withdrawn
- 2010-02-17 JP JP2011550322A patent/JP2012518014A/ja not_active Withdrawn
- 2010-02-17 CA CA2751032A patent/CA2751032A1/en not_active Abandoned

Also Published As

Publication number	Publication date
RU2011138165A (ru)	2013-03-27
US20120070403A1 (en)	2012-03-22
WO2010096446A1 (en)	2010-08-26
CA2751032A1 (en)	2010-08-26
JP2012518014A (ja)	2012-08-09
AU2010216083A1 (en)	2011-08-18
CN102316891A (zh)	2012-01-11
EP2398493A1 (en)	2011-12-28

Similar Documents

Publication	Publication Date	Title
BRPI1008955A2 (pt)	2015-09-01	Terapia de combinação com derivados de tiocolchicina.
LTPA2018001I1 (lt)	2018-02-12	Suderinta terapija, skirta LOPL
ATE526024T1 (de)	2011-10-15	Fluvoxamin vermeidende pirfenidontheraphy
BRPI1013698A2 (pt)	2016-04-26	métodos para tratamento com o uso de terapia de combinação
LT3192529T (lt)	2020-06-25	Amatoksinu užtaisyti terapiniai su ląstelės paviršiumi susirišantys komponentai, sukonstruoti navikų terapijai
BR112013013311A2 (pt)	2017-09-19	agente terapêutico de indução de citotoxicidade
EP2405749A4 (en)	2012-08-22	THERAPY TO LOW FREQUENCY GLATIRAMERATE ACETATE
EP2800530A4 (en)	2015-07-01	TRANSFORMERS FOR HISTOTRIPSIA THERAPY
BRPI1006438A2 (pt)	2016-09-27	terapia adjuvante de cancer
DK3018116T3 (da)	2021-01-25	Vitamin k2-intermediater
BR112012000502A2 (pt)	2017-05-16	terapia de combinação para o tratamento de diabetes
BRPI0812040A2 (pt)	2014-10-21	Indicações para terapia de anti-il-i-beta
BRPI1007995A2 (pt)	2019-09-24	orto-aminoamidas para o tratamento de cãncer.
BRPI0911577A2 (pt)	2016-01-05	derivados espiro-indol para o tratamento de doenças parasíticas.
BRPI0910534A2 (pt)	2015-09-29	terapia antiviral
IT1396935B1 (it)	2012-12-20	Uso di una combinazione per il trattamento delle mucositi indotte da radiazioni o da chemioterapici
BRPI0821248A2 (pt)	2015-06-16	Inibidores de cinesina como fármacos terapêuticos para câncer
BR112014002830A2 (pt)	2017-06-13	fotossensibilizador para uso terapêutico
BRPI0906606A2 (pt)	2015-07-14	Tratamento terapêutico para condições do pulmão.
ES2714390T8 (es)	2019-07-02	Aplicador de terapia con ultrasonidos
BRPI0920743A2 (pt)	2016-09-20	ribonucleases terapeuticas
EP2568806A4 (en)	2013-09-11	THERAPEUTIC DIAGRAMS
BRPI0820410A2 (pt)	2015-05-19	Lactans substituídos terapêuticos
BRPI0818598A2 (pt)	2017-05-16	agentes terapêuticos - 802
BRPI1011870A2 (pt)	2016-03-29	método para a produção de uma vidraça com reflexão reduzida, vidraça, e, uso de uma vidraça

Legal Events

Date	Code	Title	Description
2016-09-06	B08F	Application fees: application dismissed [chapter 8.6 patent gazette]	Free format text: REFERENTE AS 3A, 4A, 5A E 6A ANUIDADES.
2016-12-20	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2383 DE 06-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.